Nanotechnology based drug delivery system(s) for the management of tuberculosis.
The era of nanotechnology has allowed new research strategies to flourish in the field of drug delivery. Nanoparticle-based drug delivery systems are suitable for targeting chronic intracellular infections such as tuberculosis. Polymeric nanoparticles employing poly lactide-co-glycolide have shown promise as far as intermittent chemotherapy in experimental tuberculosis is concerned. It has distinct advantages over the more traditional drug carriers, i.e. liposomes and microparticles. Although the experience with natural carriers, e.g. solid lipid nanoparticles and alginate nanoparticles is in its infancy, future research may rely heavily on these carrier systems. Given the options for oral as well as parenteral therapy, the very nature of the disease and its complex treatment urges one to emphasize on the oral route for controlled drug delivery. Pending the discovery of more potent antitubercular drugs, nanotechnology-based intermittent chemotherapy provides a novel and sound platform for an onslaught against tuberculosis.
Pandey
Rajesh
R
Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012, India.
Khuller
G K
GK
D000818:Animals; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D006168:Guinea Pigs; D051379:Mice; D036103:Nanotechnology; D014376:Tuberculosis / Q000188:drug therapy*
D000995:Antitubercular Agents